secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001437749-24-033922
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback
--------------------------------------------------------------------------------

- Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.
- Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.
- Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.
- Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.
- Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/0001437749-24-033922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924033922/opk20241029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer